News Archive

The Duke Clinical Research Institute (DCRI) and HumanFirst announced today the creation of a new Digital Measures Evaluation Center for assessing sensors and other digital measures used in clinical research. HumanFirst, previously known as Elektra Labs, is a technology company leading the development of digital platforms to evaluate and enable the deployment of connected technologies in decentralized trials and virtual care.

A large pragmatic study in idiopathic pulmonary fibrosis (IPF) found that antimicrobial therapy did not have a statistically significant effect on respiratory hospitalization or death compared with usual care alone.

Following the presentation of results from DCRI’s ADAPTABLE

The late-breaking clinical trial found no difference between the intervention group and the control group when examining an audit and feedback initiative that was hypothesized to improve heart failure care. An effort to improve the quality of heart failure care focused on audit and feedback did not significantly improve either the outcomes of patients with heart failure or the quality of care they received, according to late-breaking clinical trial results presented today at the American College of Cardiology’s 70th annual Scientific Session & Expo.

Late-breaking clinical trial results provide new insight into how to treat patients who are hospitalized with COVID-19 and at risk for blood clots. Findings from the ACTION trial, which was led by the Brazilian Clinical Research Institute in collaboration with DCRI’s Renato Lopes, MD, PhD, were presented by Lopes Sunday at the American College of Cardiology’s 70th annual Scientific Session & Expo. Results were also published after the conference in The Lancet.

Results from a landmark clinical trial that sought to determine the safest and most effective dose of aspirin for patients with existing cardiovascular disease were presented Saturday morning as part of the 70th annual American College of Cardiology Scientific Session & Expo.

The DCRI has received $44 million in funding to examine whether three immune modulators help prevent overactive immune response in moderate or severe cases of COVID-19.

The Antibacterial Resistance Leadership Group (ARLG) involves over 100 experts, generating over 155 papers and initiating 55+ studies with 21,000 participants at 130 sites in 12 countries.

More than twice as many patients saw changes in their patient-reported outcome measures compared with their traditional NYHA measures used by clinicians.

North Carolina models the way for national discussion and decisions on school re-openings during COVID-19 pandemic.